{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:55:17Z","timestamp":1794412517391,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PE_00000019"],"award-info":[{"award-number":["PE_00000019"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP: I53C22001440006"],"award-info":[{"award-number":["CUP: I53C22001440006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.annonc.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:49:50Z","timestamp":1760798990000},"page":"79-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-6288","authenticated-orcid":false,"given":"P.","family":"Cirac\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1036-5869","authenticated-orcid":false,"given":"M.M.","family":"Germani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-6339","authenticated-orcid":false,"given":"P.","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-4136","authenticated-orcid":false,"given":"V.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mannavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-0955","authenticated-orcid":false,"given":"E.","family":"Fenocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"De Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-240X","authenticated-orcid":false,"given":"A.","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Claravezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-0719","authenticated-orcid":false,"given":"L.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-4005","authenticated-orcid":false,"given":"E.","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-9269","authenticated-orcid":false,"given":"R.","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"G.","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-4047","authenticated-orcid":false,"given":"L.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3777-8471","authenticated-orcid":false,"given":"D.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-4841","authenticated-orcid":false,"given":"C.","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Formica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Cristiano","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parlagreco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Simionato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Editta","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Dell\u2019Aquila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Zucchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Buonadonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ballestrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Berenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam Katja","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Cupini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Frisinghelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sonaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2025.10.002_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-024-00965-0","article-title":"Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm","volume":"22","author":"Cirac\u00ec","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.002_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.019","article-title":"Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies","volume":"170","author":"Rossini","year":"2022","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.annonc.2025.10.002_bib3","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1200\/JCO.2015.61.2887","article-title":"Impact of subsequent therapies on outcome of the FIRE-3\/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer","volume":"33","author":"Modest","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9863","key":"10.1016\/j.annonc.2025.10.002_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.002_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2025.10.002_bib6","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.002_bib7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10395","key":"10.1016\/j.annonc.2025.10.002_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.annonc.2025.10.002_bib9","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.002_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.002_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdy526","article-title":"REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients","volume":"30","author":"Shitara","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.10.002_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2023.02.006","article-title":"Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials","volume":"184","author":"Rossini","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2025.10.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113975","article-title":"A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness","volume":"202","author":"Yoshino","year":"2024","journal-title":"Eur J Cancer"},{"issue":"7404","key":"10.1016\/j.annonc.2025.10.002_bib14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.002_bib15","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-06-4158","article-title":"Oncogenic activation of the RAS\/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies","volume":"67","author":"Benvenuti","year":"2007","journal-title":"Cancer Res"},{"issue":"7404","key":"10.1016\/j.annonc.2025.10.002_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.002_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.5245","article-title":"Efficacy of Sym004 in patients with metastatic colorectal cancer with acquired resistance to anti-EGFR therapy and molecularly selected by circulating tumor DNA analyses: a phase 2 randomized clinical trial","volume":"4","author":"Montagut","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.002_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.22.01423","article-title":"Resistance mechanisms to anti-epidermal growth factor receptor therapy in RAS\/RAF wild-type colorectal cancer vary by regimen and line of therapy","volume":"41","author":"Parseghian","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.002_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.22.00365","article-title":"Acquired genomic alterations on first-line chemotherapy with cetuximab in advanced colorectal cancer: circulating tumor DNA analysis of the CALGB\/SWOG-80405 trial (Alliance)","volume":"41","author":"Raghav","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.002_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.10.002_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.946850","article-title":"Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer","volume":"12","author":"Cremolini","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.002_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.002_bib23","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.002_bib24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2019.37.4_suppl.585","article-title":"Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: additional study of E-rechallenge trial","volume":"37","author":"Ohhara","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.002_bib25","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/j.annonc.2024.08.580","article-title":"511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial","volume":"35","author":"Vivas","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.002_bib26","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2022.40.16_suppl.3518","article-title":"Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS\/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials","volume":"40","author":"Kagawa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.002_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/PO.20.00109","article-title":"RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer","author":"Sunakawa","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.002_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.002_bib29","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2022.40.16_suppl.3520","article-title":"Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer","volume":"40","author":"Parseghian","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.002_bib30","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.002_bib31","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.002_bib32","first-page":"141","article-title":"Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: neutrophil to lymphocyte ratio predicts survival","volume":"21","author":"Ciardiello","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.002_bib33","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/ijc.34632","article-title":"Panitumumab plus trifluridine\/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial","volume":"153","author":"Napolitano","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2025.10.002_bib34","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2025.43.16_suppl.3514","article-title":"Longitudinal ctDNA monitoring and prediction of anti-EGFR rechallenge outcomes in RAS\/BRAF wild-type metastatic colorectal cancer (mCRC): the REMARRY & PURSUIT trials","volume":"43","author":"Kagawa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.002_bib35","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.annonc.2024.05.014","article-title":"3O PRODIGE 68 - UCGI 38 - SOREGATT: a randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine\/tipiracil (t\/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)","volume":"35","author":"Ducreux","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.10.002_bib36","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2025.43.16_suppl.3513","article-title":"FIRE-4 (AIO KRK-0114): randomized study evaluating the efficacy of cetuximab re-challenge in patients with metastatic RAS wild-type colorectal cancer responding to first-line treatment with FOLFIRI plus cetuximab","volume":"43(suppl 16)","author":"Weiss","year":"2025","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.annonc.2025.10.002_bib37","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.10.002_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115399","article-title":"Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: an exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer","volume":"221","author":"Weiss","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:59:53Z","timestamp":1777582793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0923753425049348"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}